Sopherion Therapeutics
closedSopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD291—436m (Dealroom.co estimates Sep 2004.)
New Brunswick New Jersey (HQ)
Authorizing premium user...